✕
Login
Register
Back to News
Ionis Pharmaceuticals Announces License Agreement With Recordati For Zilganersen In Alexander Disease In All Countries Outside The US For $30M Upfront Payment
Benzinga Newsdesk
www.benzinga.com
Positive 72.9%
Neg 0%
Neu 0%
Pos 72.9%
- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments -
- Ionis to independently commercialize zilganersen in the U.S. assuming FDA approval -
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment